

FOSTOT 60584660




Fig. 1




Fig. 2






Fig. 3

-Focal Adhesions (-FA)




*Fig. 4A*


+Focal Adhesions (+FA)



*Fig. 4B*



*Fig. 4C*



*Fig. 4E*

*Fig. 4D*

06978309-10501





Fig. 5




*Fig. 6A*




*Fig. 6B*

TOSTOT 60E82660




*Fig. 7A*




*Fig. 7B*

FOSTOT 60EB2660




*Fig. 8*




*Fig. 9*

FOSTOT 6022660






*Fig. 10*



IL-1

*Fig. 11A*




TNFα

*Fig. 11B*

09978309-101501


FOSTOT 60E82660




+RHAMM cells make less focal contacts than their parental cells (-RHAMM)

*Fig. 12A*

*Fig. 12B*




• Overexpression of RHAMM results in increased and sustained production of podosomes




• In most cells responding to injury, podosomes are formed and disassembled rapidly (-RHAMM, 6 vs. 24 hrs)


Fig. 13



*Fig. 14A*



*Fig. 14B*



*Fig. 14C*

FOOT 60E82660




Fig. 14D      Fig. 14E      Fig. 14F

FOSTOT 60EB2660




Fig. 15A

RHAMM Peptides

Murine Exon3 sequence:

N-terminal ---KLQATQKDLTESKGKIVQLEGKL--- 23aa

SEQ ID. NO. 14

For Exon3 antibody, used the peptide sequence:

(C) KLQATQKDLTESKG

SEQ ID. NO. 15

Murine Exon4 sequence:

N-terminal ---VSIEKEKIDEKCETEKLLEYIQEIS--- 25aa

SEQ ID. NO. 16

For Exon4 antibody, used the peptide sequence:

(C) VSIEKEKIDEKC/S

SEQ ID. NO. 17

For antibody to Human RHAMM v5, used the peptide sequence:

(C) LKSKFSENGNQKNL

SEQ ID. NO. 18


Homology between three peptides from murine (M) and human (H) RHAMM (as used to raise antibody)

1) Exon3	M:	KLQATQKDLTESKG	as in	SEQ ID. NO. 15
	H:	---V--RS-E-Q--		SEQ ID. NO. 19
2) Exon4	M:	VSIEKEKIDEKC	as in	SEQ ID. NO. 17
	H:	-----S	as in	SEQ ID. NO. 17
3) v5	M:	--A----D-H---M		SEQ ID. NO. 20
	H:	LKSKFSENGNQKNL	as in	SEQ ID. NO. 18

Fig. 15B

peptide 1


peptide 2




*Fig. 16A*

*Fig. 16B*







*Fig. 16C*



*Fig. 16D*



*Fig. 17A*



*Fig. 17B*

FOSTOT 6082660




Fig. 18

FOOTNOTES







Fig. 19




*Fig. 20A*




*Fig. 20B*




*Fig. 21A*




*Fig. 21B*



*Fig. 21C*




*Fig. 22*




Effects of Exon4 Antibody and LZIP  
 on the Podosome Formation of LR21


*Fig. 24A*



*Fig. 23A*



*Fig. 23B*



*Fig. 24B*

09978309-101501





Fig. 25A




Fig. 25B






Fig. 25C

A: RGGGRGRRR  
 B: RGGGRGGRR  
 C: RGGGRGGGR  
 D: RGGGGGGGR


*Fig. 26A*




*Fig. 26B*



*Fig. 26C*



*Fig. 27*



*Fig. 28*




Fig. 29





Fig. 30




Fig. 31








Fig. 32


FOSTOT 60382660




*Fig. 33*



*Fig. 34*



*Fig. 35A*



*Fig. 35B*




Fig. 36

Patient	% of total X4+ cells	% of total V5+ cells	Neutrophils			Monocytes/macrophages			T cells		
			% of total cells	% of X4+ cells	% of V5+ cells	% of total cells	% of X4+ cells	% of V5+ cells	% of total cells	% of X4+ cells	% of V5+ cells
W.H.	ND	50.7	70.5	81.2	ND	21.8	87.1	66.4	6.7	11.7	13.0
M.T.	74.6	20.7	80.7	ND	9.9	11.2	89.6	ND	9.0	<2.0	ND
L.S.	43.9	34.4	ND	ND	ND	8.5	ND	53.8	20.4	5.3	<2.0
S.M.	67.6	4.0	67.3	80.9	ND	ND	ND	ND	3.0	10.0	<2.0
M.M.	19.2	19.6	25.2	68.3	ND	ND	ND	ND	2.7	4.5	8.0
D.D	35.7	31.2	40.7	99.3	ND	ND	ND	ND	6.9	<2.0	9.9
P.B. (r)	77.4	71.8	ND	ND	ND	9.2	99.8	88.3	4.4	13.0	33.2
P.B. (l)	85.0	82.3	ND	ND	ND	12.8	99.4	58.3	3.4	11.0	30.2
S.L.	51.6	45.5	61.7	92.1	77.2	8.8	73.4	85.6	24.0	6.0	9.0
R.C.	10.6	6.7	54.1	63.8	13.8	5.6	50.3	43.9	6.3	8.5	11.9
N.N.	27.9	10.3	44.1	54.6	21.4	3.5	77.1	49.4	6.8	33.1	22.2
M.G	85.48	84.63	86.7	99.6	99.5	5.52	98.7	98.9	6.36	4.8	7.6

• ND - non-determined

- (r) - right knee

- (l) - left knee

Fig. 37

APPLN. FILING DATE: FILED HERewith


**TITLE: COMPOSITIONS AND METHODS FOR TREATING CELLULAR RESPONSE TO INJURY AND ...**

**INVENTOR(S): TONY CRUZ, ET AL.**

ATTORNEY DOCKET NO.: 033352-010

**SHEET 38 of 63**





*Fig. 38*

09978309-101501-105101




Fig. 39






Fig. 40A




Fig. 40B







Fig. 41



*Fig. 42*



*Fig. 43A*



*Fig. 43B*

033352-010-101501






Fig. 44A

TOP SECRET



*Fig. 44B*



Note: This effect is not being seen with NOD mice

*Fig. 45*




Fig. 46A




Fig. 46B






Fig. 47A






Fig. 47B



*Fig. 48A*




*Fig. 48B*

09978309 101501


RHAMM binding protein cDNA (RABP) (partial)

GAA TTC GCG GCG GCG TCG ACC AAC AAG CCC CCT GCT GTT TCC CCG GGG  
 E F A A A S T N K P P A V S P G  
 GTG GTC TCC CCA ACC TTT GAA CTT ACA AAT CTT CTA AAT CAT CCT GAC  
 V V S P T F E L T N L L N H P D  
 CAT TAT GTA GAA ACA GAG AAC ATT CAG CAT CTC ACA GAC CCG GCT CTA  
 H Y V E I E N I Q H L T D P A L  
 GCA CAT GTG GAT AGA ATA AGC GAA GCC CGG AAA CTG AGT ATG GGA TCT  
 A H V D R I S Q A R K L S M G S  
 GAT GAT GCT GCC TAC ACA CAA GCT CTG CTG GTG CAC CAG AAG GCC AGG  
 D D A A Y T Q A L L V H Q K A R  
 ATG GAA CGG CTT CAA AGA GAG CTC GAG ATG CAA AAG AAA AAG CTG GAT  
 M E R L Q R E L E M Q K K K L D  
 AAA CTC AAA TCT GAG GTC AAT GAG ATG GAA AAT AAT CTA ACT CGA AGG  
 K L K S E V N E M E N N L T R R  
 CGC CTG AAG AGA TCA AAT TCC ATT TCC CAG ATA CCG TCA CTC GAA GAA  
 R L K R S N S I S Q I P S L E E  
 ATG CAG CAG TTG AGA AGT TGT AAT AGA CAA CTC CAG ATT GAC ATT GAC  
 M Q Q L R S C N R Q L Q I D I D  
 TTT GAC TGC TTA ACC AAA GAA ATT GCA TCT TTT TCA AGC CCG AGG ACC  
 F D C L T K E I A S F S S P R T  
 ACA TTT TAA CCC CAG CGC TAT TCA TAA CTT TTA TGA CAA TAT TGG ATT  
 T F \*  
 TGT AGG CCC TGT GCC ACC AAA ACC CAA AGA TCA AAG GTC CAC CAT CAA  
 AGG TCG ACG CGG



Fig. 49A-



*Fig. 49B*



*Fig. 49C*



*Fig. 49D*

Human: 76 KESQKNDKDKILEKEIRVLLQERGAQDRRIQDLETELEKMEARLNAALREKTSLSANNATLEKQI IELTRTNEL

Mouse: 1      MRALSLEMLKLRNKRRETKMRSMMVMKQEGMELKLQATQKDLTESKGIQVQLEGKLVSEKEKI

Mouse: 63 DEKCETEKLL EYIQEISCASDOVECKVDIAQLEEDLKEKDREILSKQSL EENITF-SKQIEDLTVKCOLLETE

Mouse: 138 RNDLVSKDRERAETLSAEMQILTERLALERQEYEKLOQKELQSQSLLOQEKEL SARLQQQLCSFQEEMTSEKNVF

Mouse: 213 KEELKLALAE L DAVQQKEEQSERLVKQLEERKSTAEQLTRLDNLLREKEVELEKHIAAHQAAILIAQEKYNDTA

Human: .....

Mouse: 288 QSLRDVTAQLESVQEKYNTAQSLRDVTAQLESEQEKYNTAQSLRDVTAQLESEQEKYNTAQSLRDVTAQLES

Mouse: 363 QEKYNDTAQSLRDVTAQLESYKSSTLKEIEDLKLENLTLQEKVAMAEKSVEDVQQILTAESTNQEYARMQDLO

Mouse: 438 NRSTLKEEEIKEITSSFLEKITDLKNQLROODEDFRKOLEEKGRKRTAEKENVMTLMEINKWRLLYEELYEYTK


```

|||||+|||||+|
Mouse: 513 PF000DAFEAEKOALLNEHGATQEQLNKIRDSYAQLLGHONLKQKIKHVVKLKDENSOLKSEVSKLRSOLVKRK

```


house: 588 ONELROGELDKALGIRHFDPSKAFCHASKENF---TPLKEGNPNCC\*

*Fig. 50*



Note: normal blood glucose level = 99-140  
Incidence of abnormal blood glucose level in NOD mice

*Fig. 51*



Incidence of abnormal urine glucose level in NOD mice

*Fig. 52*

POSTOFF 60E82660






Fig. 53






Note: 2 untreated animals died during the course of experiment  
Effect of P- 16 peptide on kidney weight in NOD mice


*Fig. 54*



*Fig. 55*



*Fig. 56*



*Fig. 57*






Fig. 58



*Fig. 59.*



*Fig. 60*